Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal cancer, esophageal disorder, head and neck squamous cell carcinoma, kidney cancer, kidney disorder, neoplasm, non-small cell lung carcinoma, renal cell carcinoma, skin squamous cell carcinoma, squamous cell carcinoma, transitional cell carcinoma, urinary system disorder, urothelial carcinoma	Recruiting	Not stated	2025-09-17		NCT04892849

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
University of Erlangen-Nürnberg Medical School	47

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Department of Radiation Oncology, Universitätsklinikum Erlangen	Erlangen	Germany	3